<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04589494</url>
  </required_header>
  <id_info>
    <org_study_id>493</org_study_id>
    <nct_id>NCT04589494</nct_id>
  </id_info>
  <brief_title>Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain</brief_title>
  <official_title>Comparison Between the Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this work is looking for comparison between the effect of tramadol versus morphine on PD1 and&#xD;
      PD1-ligand in patients with chronic cancer pain&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of opioids is the mainstay in the treatment of many types of chronic pain, including&#xD;
      cancer and non-cancer-related pain]. Opioids are known to suppress immune function following&#xD;
      both acute and chronic administration; however, they appear to be different according to the&#xD;
      schedule of administration as well as the state of the organism. Programmed death-1 (PD-1,&#xD;
      also known as CD279) belongs to the CD28 receptor superfamily. It is an inhibitory receptor,&#xD;
      and its expression is upregulated on activated leukocytes, resulting in an inhibited immune&#xD;
      response. PD-1 interacts with two ligands: programmed death ligand-1 (PD-L1, also referred to&#xD;
      as B7-H1) and programmed death ligand-2 (PD-L2, also known as B7-DC). PD-L2 is expressed&#xD;
      mainly on activated dendritic cells (DCs) and macrophages, whereas PD-L1 is distributed&#xD;
      widely. In addition to immune cells, some subsets of tumor cells also express PD-L1 to escape&#xD;
      from immunosurveillance. It has been reported that the PD-1/PD-L1 pathway could be activated&#xD;
      by surgical stress.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>tramadol or morphine</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>changes in PD1 and PD1ligand</measure>
    <time_frame>baseline(0), day15 , day 30</time_frame>
    <description>this is flow cytomertic analyses to the human peripheral blood mononuclear cells (PBMCs) will be separated with a Ficoll-Isopaque density gradient. Flow cytometric analyses will be carried out immediately.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain assessment</measure>
    <time_frame>baseline(0), day15 ,day 30</time_frame>
    <description>patient describ his pain severty from 0= no pain to 10= the most sever pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>tramadol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tramadol hydrochloride 100 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>morphine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>morphine 30 mg twise times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Hydrochloride</intervention_name>
    <description>tramadol hydrochloride 100 mg three times daily , morphine sulphate 30 mg twice daily</description>
    <arm_group_label>morphine group</arm_group_label>
    <arm_group_label>tramadol group</arm_group_label>
    <other_name>morphine sulphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with cancer pain of varying etiology,&#xD;
&#xD;
          -  documented metastatic cancer, currently on step I WHO ladder and whose pain&#xD;
             necessitates a shift to step II,&#xD;
&#xD;
          -  those who have never received radiotherapy, chemotherapy, or immunosuppressive drugs,&#xD;
             -- and in good general and nutritional condition and without infectious diseases at&#xD;
             the time of investigation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  abnormal hepatic, renal, and pulmonary function, gastrointestinal pathology, and&#xD;
&#xD;
          -  those with cerebral metastases and/or psychological disorders,&#xD;
&#xD;
          -  patients with contraindication to morphine or tramadol according to their respective&#xD;
             data sheets, and&#xD;
&#xD;
          -  patients who could not complete the diary information correctly.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shereen M Kamal, Associate Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>shereen M Kamal, Associate professor</last_name>
    <phone>01006279209</phone>
    <email>sheridouh79@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hassan M Kotb, Professor</last_name>
    <phone>01287332042</phone>
    <email>kotbhi@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assiut University</name>
      <address>
        <city>Assiut</city>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sahar A. Mohamed, MD</last_name>
      <phone>01003611410</phone>
      <email>drsaher2008@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Shereen M. Mohamed, MD</last_name>
      <phone>01006279209</phone>
      <email>sheridouh79@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Shereen Mamdouh</investigator_full_name>
    <investigator_title>Lectruer of anesthesia, ICU and pain manegement</investigator_title>
  </responsible_party>
  <keyword>morphine</keyword>
  <keyword>tramadol</keyword>
  <keyword>PD1 and PD1 ligand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Cancer Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

